What does a GP do for a kidney transplant patient differently from other patients?

Several things differ critically. First, no live vaccines ever — transplant patients cannot receive MMR, varicella, Zostavax, oral typhoid, BCG, or yellow fever; this is lifelong. Second, drug interaction vigilance around tacrolimus and ciclosporin — CYP3A4 substrates — means common medications (macrolides, azoles, diltiazem, verapamil, grapefruit) can cause dangerous calcineurin inhibitor toxicity or rejection. Third, skin cancer surveillance is annual and mandatory — SCC risk is 65–250 times higher than the general population; this is not optional screening. Fourth, never prescribe NSAIDs for pain in a transplant patient with a functioning graft (nephrotoxic; reduce GFR). Fifth, rising creatinine is a transplant unit call the same day, not a 'watch-and-wait'.

What are the warning signs of acute rejection?

Acute rejection does not always cause pain. The earliest sign is often a rising serum creatinine — even a 25% rise above baseline warrants same-day contact with the transplant nephrology unit. Other features: decreased urine output, graft tenderness (graft is in the lower abdomen), fever, and elevated inflammatory markers (CRP, white cell count). Note that chronic antibody-mediated rejection (the most common cause of late graft loss) is typically silent and detected only on routine monitoring. Transplant patients should have creatinine checked every 3 months for the first year post-transplant and at least twice yearly when stable, per KDIGO 2009 and TSANZ guidelines.

Why are kidney transplant patients at such high risk of skin cancer?

Immunosuppression — particularly calcineurin inhibitors (tacrolimus, ciclosporin) and azathioprine — reduces immune surveillance of skin cancer cells and increases susceptibility to oncogenic viruses (HPV subtypes driving squamous cell carcinoma). The ANZDATA registry shows SCC risk 65–250 times higher than the general population. NMSC (non-melanoma skin cancer, primarily SCC) is the most common cancer post-transplant, exceeding all other post-transplant malignancies combined. The distribution is different from the general population — transplant patients get more SCC relative to BCC, and the lesions are more aggressive. Annual full-skin examination by a dermatologist, daily SPF 50+ broad-spectrum sunscreen, sun-protective clothing, and avoidance of peak UV hours are non-negotiable in Australian conditions.

Which medications are dangerous to prescribe to a kidney transplant patient?

The critical interaction list centres on calcineurin inhibitors (tacrolimus, ciclosporin), which are narrow-therapeutic-index CYP3A4 substrates. Dangerous interactions: clarithromycin and erythromycin (CYP3A4 inhibitors — can triple or quadruple tacrolimus levels → toxicity/nephrotoxicity); azole antifungals fluconazole, itraconazole, voriconazole, posaconazole (similarly potent CYP3A4 inhibitors); diltiazem and verapamil (moderate CYP3A4 inhibitors); HIV protease inhibitors; grapefruit (CYP3A4 inhibition). Rifampicin is a potent CYP3A4 inducer — causes precipitous drop in tacrolimus levels → rejection risk. St John's wort: inducer — can cause rejection; many patients don't mention it. Probenecid and ACE inhibitors/ARBs can affect tacrolimus levels or renal function in the transplant. NSAIDs: avoid — reduce GFR, risk of acute kidney injury in transplant. Always check AMH or contact the transplant pharmacist before adding any new medication.

What vaccinations does a kidney transplant patient need?

All vaccinations must be inactivated — live vaccines are permanently contraindicated post-transplant. The ATAGI immunocompromised schedule applies: annual inactivated influenza (essential — infections trigger rejection); COVID-19 booster doses (higher doses and more frequent recommended for solid organ transplant patients per TGA/ATAGI guidance); Prevenar 20 (or Prevenar 13 → PPSV23 at 8 weeks, repeat at 5 years); MenACWY + MenB; Hib; hepatitis A + B complete series; dTpa. Shingrix (recombinant, non-live zoster vaccine) is NIP-funded for severely immunocompromised adults since 2023. Catch-up live vaccines (MMR, varicella) must occur before transplant, not after.

Kidney transplant in general practice

Kidney transplant in general practice: the AU GP approach

By Dr HB Lo, FACRRM Reviewed 26 September 2026 9 min read

Australia has ~14,000 kidney transplant recipients and ~1,400 new transplants per year — transplant shared care is a core GP competency.

Seven GP workstreams: immunosuppression continuity, infection prophylaxis, vaccination (no live vaccines ever), cancer surveillance (SCC risk 65–250× — annual dermatology mandatory), comorbidity management (hypertension, NODAT, dyslipidaemia), drug interaction vigilance, bone health.

Never alter immunosuppression independently. Rising creatinine, fever, or a suspicious skin lesion each warrant same-day contact with the transplant nephrology unit.

Kidney transplant recipients in Australian general practice

Australia performs approximately 1,400 kidney transplants per year and has around 14,000 kidney transplant recipients alive, per the ANZDATA 44th Annual Report 2024. With 1-year graft survival of ~95% (deceased donor) and ~99% (living donor), and 10-year survival of ~70–80%, these patients live long enough to have regular, ongoing GP care.

Kidney transplantation provides far better quality-adjusted life years than dialysis, and most recipients return to near-normal daily function. But they carry a lifelong, modified biological state: permanent immunosuppression, altered drug handling, and a dramatically different risk profile for infection, malignancy, and cardiovascular disease. GP shared care with the transplant nephrology unit is the care model — not independent management.

This article covers what a GP needs to know for confident, safe transplant shared care, anchored to TSANZ guidelines, KDIGO 2009, ANZDATA 2024, eTG, and AMH.

A. Core clinical — the AU general-practice framework

The first GP visit with a transplant patient

Establish a complete picture and document prominently in the patient record:

Transplant date and centre — which hospital, which nephrologist
Donor type — deceased donor (DBD or DCD) vs living donor (related, unrelated, paired)
Baseline post-transplant creatinine (steady-state value, typically by 3–6 months post-transplant) — the reference point for all future monitoring
Current immunosuppression regimen — agent, dose, frequency, formulation (tacrolimus IR vs ER matters)
Recent tacrolimus trough levels — aim range varies by centre and time post-transplant (commonly 8–12 µg/L at 3–6 months, lower 5–8 µg/L when stable)
History of rejection episodes — how many, type (cellular vs antibody-mediated), treatment
History of post-transplant infections — CMV, BK virus, fungal
Current cancer surveillance — last dermatology review, NCSP cervical screening status, bowel screening
Vaccination status — all vaccines documented; confirm no live vaccines were given post-transplant
Shared care letter from transplant unit — obtain if not already in the file

Routine monitoring — the GP’s checklist

At each consultation (3-monthly for first year, 6-monthly when stable):

Parameter	Frequency	Target / action
Serum creatinine (and eGFR)	Each visit	Compare to baseline; rise ≥25% → same-day transplant centre
Urinalysis	Each visit	Haematuria (BK virus, rejection, malignancy); proteinuria (urine ACR)
FBC	Each visit	Leucopenia (CMV, mycophenolate toxicity); anaemia (CKD of graft, erythropoietin)
LFTs	3-monthly	Hepatotoxicity; mycophenolate-related
Glucose and HbA1c	3–6-monthly	NODAT (new-onset diabetes after transplant) — affects ~25% within 3 years
Lipids	Annually	CV risk; statin indicated per KDIGO
Calcium, phosphate, PTH	6-monthly	Tertiary hyperparathyroidism; osteoporosis
Tacrolimus trough level	Per specialist instruction, at routine check, at every dose change or suspected interaction	Narrow therapeutic index
Blood pressure	Each visit	Target below 130/80 per KDIGO 2024
Skin examination	Annually (dermatologist); brief at every GP visit	SCC risk 65–250× general population

Immunosuppression — what the GP maintains

TSANZ and eTG specify standard maintenance triple therapy, all PBS Section 100 Highly Specialised Drugs, specialist-initiated:

Calcineurin inhibitor (CNI): Tacrolimus (most common) or ciclosporin. GPs write continuing prescriptions; do NOT adjust the dose independently — even small dose changes shift trough levels significantly.
Antiproliferative: Mycophenolate mofetil (1 g BD) or mycophenolate sodium, or azathioprine (1–2 mg/kg/day). Mycophenolate is associated with GI adverse effects (diarrhoea, nausea) — dose adjustment requires specialist input.
Corticosteroid: Prednisolone 5 mg daily. Some protocols wean steroids after 3–6 months; others continue lifelong. Long-term steroid effects: Cushingoid features, osteoporosis, glucose intolerance.

Never independently stop, reduce, or switch immunosuppression. Even apparent adverse effects require transplant unit consultation before changes.

B. The seven critical workstreams

1. Drug interactions — the must-not-miss list

Tacrolimus and ciclosporin are narrow-therapeutic-index CYP3A4 substrates. AMH and eTG identify these as absolute or near-absolute contraindications to co-prescription without transplant pharmacist input:

CYP3A4 inhibitors (raise CNI levels → toxicity/nephrotoxicity):

Macrolide antibiotics: clarithromycin, erythromycin — can 3–4× tacrolimus levels acutely; azithromycin is a safer antibiotic alternative
Azole antifungals: fluconazole, itraconazole, voriconazole, posaconazole, ketoconazole — topical azoles are generally safe (minimal systemic absorption)
Calcium channel blockers: diltiazem, verapamil — clinically significant; amlodipine is safer
HIV protease inhibitors
Grapefruit and pomelo juice

CYP3A4 inducers (lower CNI levels → rejection risk):

Rifampicin — precipitous 10-fold drop in tacrolimus; if TB must be treated, transplant unit coordinates alternative regimen
St John’s wort — patients often don’t disclose; ask specifically

Nephrotoxins to avoid:

NSAIDs — reduce glomerular filtration and cause acute kidney injury in the transplant; prefer paracetamol for analgesia
Aminoglycosides — if unavoidable (serious infection), close renal monitoring and transplant unit involvement

2. Infection prophylaxis and surveillance

Per eTG and TSANZ:

Pneumocystis jirovecii pneumonia (PJP): TMP-SMX 480 mg (one single-strength tablet) daily for the first 6–12 months post-transplant; consider continuing if ongoing high-dose immunosuppression. GPs should confirm this is still prescribed at each early review.
CMV prophylaxis: Valganciclovir 450–900 mg daily for 100–200 days when donor is CMV-seropositive and recipient is seronegative (D+/R− highest risk). CMV disease (fever, graft dysfunction, CMV retinitis) requires urgent transplant unit review.
BK polyomavirus: Asymptomatic rising BK viraemia detected on routine surveillance PCR warrants immunosuppression reduction by the transplant unit; BK nephropathy → rising creatinine.
Oral candidiasis: Clotrimazole troches or nystatin oral suspension first-line. If recurrent or oropharyngeal, consider systemic fluconazole with transplant pharmacist guidance regarding CNI interaction.

3. Vaccination — the live vaccine lifeline

ATAGI immunocompromised guidance is absolute: no live vaccines ever post-transplant. This includes MMR, varicella, Zostavax, oral typhoid, BCG, yellow fever. GPs must document this permanently in the patient record and ensure practice staff are aware.

Recommended inactivated vaccines:

Inactivated influenza: annually — essential, as influenza can trigger rejection
COVID-19: per current ATAGI advice; solid organ transplant recipients qualify for additional booster doses
Prevenar 20 (or Prevenar 13 + PPSV23 8 weeks later; repeat PPSV23 at 5 years)
MenACWY and MenB (Bexsero) — especially if patient has hyposplenism
Shingrix (recombinant zoster vaccine) — NIP-funded since 2023 for severely immunocompromised adults; GPs should actively offer
Hepatitis A and B — full series; confirm seroconversion (anti-HBs titre) — response may be suboptimal; re-vaccinate if titre below 10 IU/L
dTpa — per standard schedule and following significant wounds

4. Cancer surveillance

The ANZDATA 2024 registry confirms SCC risk 65–250 times the general population — the most common post-transplant malignancy. Management:

Annual full-skin examination by a dermatologist — GP referral annually; do not wait for a lesion to appear
Daily SPF 50+ broad-spectrum sunscreen + protective clothing + sun-avoidance — counsel at every visit
Any new, changing, or ulcerating skin lesion — prompt dermatology review; don’t observe for more than 2–4 weeks
Post-transplant lymphoproliferative disorder (PTLD): ~1–2% incidence; often EBV-driven; presents as lymphadenopathy, tonsillar enlargement, systemic B symptoms, or graft dysfunction; urgent haematology referral
Cervical cancer: standard NCSP 5-yearly HPV screening, earlier if immunosuppressed (TSANZ recommends 2-yearly or per NCSP; confirm with transplant unit)
Bowel and breast cancer: standard AU population screening guidelines

5. Comorbidity management

New-onset diabetes after transplant (NODAT): Affects ~25% of recipients within 3 years. Driven by corticosteroids + tacrolimus (both impair insulin secretion and action). Manage per type-2-diabetes guidelines but note tacrolimus dose reduction (transplant unit) is the most effective intervention. Avoidance of metformin in significant renal impairment (eGFR below 45) applies as for other CKD patients.

Hypertension: Target BP below 130/80 per KDIGO 2024. Common agents: CCB amlodipine (first-line — avoids tacrolimus interaction unlike diltiazem/verapamil); ACE inhibitors or ARBs are preferred when proteinuria is present but require creatinine/potassium monitoring — discuss addition/change with transplant unit. Beta-blockers for heart disease.

Dyslipidaemia: Statin therapy per KDIGO recommendations. Pravastatin or rosuvastatin preferred due to minimal CYP3A4 interaction (fluvastatin also acceptable); simvastatin and lovastatin have significant CNI interactions and should be avoided. Atorvastatin is a weak CYP3A4 substrate — usually acceptable but use lowest effective dose.

6. Bone health

Chronic corticosteroid use + pre-existing CKD-mineral bone disease + post-transplant hypophosphataemia + hyperparathyroidism all contribute to bone loss. Per ANZSN:

Baseline DEXA within 3 months post-transplant
25(OH)D target ≥75 nmol/L; supplement to target
Calcium 1,000–1,200 mg/day through dietary intake first
Bisphosphonate (alendronate or zoledronate) for T-score below −2.5 or prior fragility fracture, after transplant unit review

7. Recognising graft complications early

Symptom / sign	Concern	Action
Rising creatinine (≥25% from baseline)	Rejection, CNI toxicity, dehydration, BK nephropathy, obstruction	Same-day transplant unit call
Fever ≥38 °C	Bacterial sepsis, CMV, BK, fungal	Same-day transplant unit or emergency
Haematuria	BK virus, rejection, malignancy	Transplant unit + urological workup
New abdominal pain	Graft tenderness = rejection; diverticulitis (higher risk on steroids); CMV colitis	Transplant unit
New lymphadenopathy	PTLD	Haematology referral
Any new skin lesion	SCC, melanoma	Urgent dermatology

D. Australian operations

Shared care documentation

When a new transplant patient presents to a GP, obtain the transplant centre shared care letter. If absent, contact the unit directly. The letter should specify: current immunosuppression, recent trough levels, monitoring intervals, action thresholds for creatinine change, and the transplant nephrologist’s contact details.

Kidney Health Australia provides GP education resources and a 24-hour nurse helpline for patient queries.

Transplant Australia and DonateLife offer patient advocacy, peer support, and return-to-sport/exercise programs.

Rural and regional GP considerations

Many transplant recipients live remotely from their transplant centre. Telehealth outreach clinics extend specialist contact. The GP is often the sole clinical interface for months between specialist reviews. In this context: reliable, timely creatinine monitoring and a low threshold for phone consultation with the transplant unit are life-saving. A rising creatinine in a rural patient is not a reason to wait for the next outreach clinic.

E. Special populations

Aboriginal and Torres Strait Islander Australians. ATSI Australians have a disproportionately high burden of end-stage kidney disease (ESKD) relative to non-ATSI Australians, with historically lower transplant access rates. Equity in access to transplantation and post-transplant follow-up is an active area of TSANZ and Kidney Health Australia policy. Cultural safety in shared care, connection to Aboriginal Community Controlled Health Organisations (ACCHOs), and liaison with the patient’s transplant centre social worker are important.

Older adults. Recipients over 65 represent a growing segment. Frailty assessment, polypharmacy review (every medication interacts or depletes renal reserve), and advance care planning conversations are appropriate. Graft outcomes in older recipients are good; quality of life is often dramatically better than dialysis.

Paediatric recipients transitioning to adult care. Adolescents transitioning from paediatric to adult transplant nephrology services are a high-risk group for non-adherence to immunosuppression. GPs play an important bridging role — rapport, consistent messaging about adherence, and mental health assessment (depression and non-adherence strongly linked).

Pregnancy post-transplant. Possible after successful transplantation but requires specialist planning. Tacrolimus is used in pregnancy; mycophenolate is contraindicated (teratogenic; must be switched to azathioprine ≥6 weeks before conception). Pregnancy post-transplant is high-risk obstetrics — coordinate transplant nephrology, maternal-foetal medicine, and GP.

When to escalate

Same-day transplant unit (phone):

Creatinine rise ≥25% above baseline
Fever ≥38 °C in a transplant patient
Suspected acute rejection (pain over graft, oliguria)
BK viraemia detected on routine PCR
Any urgent medication addition that interacts with CNI (macrolide, azole)

Urgent referral:

New skin lesion — urgent dermatology
Lymphadenopathy or tonsillar enlargement — haematology (PTLD)
Suspected CMV disease
NODAT inadequately controlled — transplant unit for IS adjustment discussion

What this article is and is not

This is general health information drawn from current Australian transplant and general practice guidelines — TSANZ, ANZDATA, KDIGO, ANZSN, eTG, AMH, ATAGI, Kidney Health Australia, and RACGP. It is not personal medical advice and does not create a doctor–patient relationship. Immunosuppression management is always coordinated with the patient’s transplant nephrology team.

For Australian patient resources: Kidney Health Australia, Transplant Australia, DonateLife.

For urgent queries outside hours: contact the transplant nephrology unit on-call at the patient’s transplant hospital.

Sources cited

Frequently asked questions

What does a GP do for a kidney transplant patient differently from other patients?

Several things differ critically. First, no live vaccines ever — transplant patients cannot receive MMR, varicella, Zostavax, oral typhoid, BCG, or yellow fever; this is lifelong. Second, drug interaction vigilance around tacrolimus and ciclosporin — CYP3A4 substrates — means common medications (macrolides, azoles, diltiazem, verapamil, grapefruit) can cause dangerous calcineurin inhibitor toxicity or rejection. Third, skin cancer surveillance is annual and mandatory — SCC risk is 65–250 times higher than the general population; this is not optional screening. Fourth, never prescribe NSAIDs for pain in a transplant patient with a functioning graft (nephrotoxic; reduce GFR). Fifth, rising creatinine is a transplant unit call the same day, not a 'watch-and-wait'.
What are the warning signs of acute rejection?

Acute rejection does not always cause pain. The earliest sign is often a rising serum creatinine — even a 25% rise above baseline warrants same-day contact with the transplant nephrology unit. Other features: decreased urine output, graft tenderness (graft is in the lower abdomen), fever, and elevated inflammatory markers (CRP, white cell count). Note that chronic antibody-mediated rejection (the most common cause of late graft loss) is typically silent and detected only on routine monitoring. Transplant patients should have creatinine checked every 3 months for the first year post-transplant and at least twice yearly when stable, per KDIGO 2009 and TSANZ guidelines.
Why are kidney transplant patients at such high risk of skin cancer?

Immunosuppression — particularly calcineurin inhibitors (tacrolimus, ciclosporin) and azathioprine — reduces immune surveillance of skin cancer cells and increases susceptibility to oncogenic viruses (HPV subtypes driving squamous cell carcinoma). The ANZDATA registry shows SCC risk 65–250 times higher than the general population. NMSC (non-melanoma skin cancer, primarily SCC) is the most common cancer post-transplant, exceeding all other post-transplant malignancies combined. The distribution is different from the general population — transplant patients get more SCC relative to BCC, and the lesions are more aggressive. Annual full-skin examination by a dermatologist, daily SPF 50+ broad-spectrum sunscreen, sun-protective clothing, and avoidance of peak UV hours are non-negotiable in Australian conditions.
Which medications are dangerous to prescribe to a kidney transplant patient?

The critical interaction list centres on calcineurin inhibitors (tacrolimus, ciclosporin), which are narrow-therapeutic-index CYP3A4 substrates. Dangerous interactions: clarithromycin and erythromycin (CYP3A4 inhibitors — can triple or quadruple tacrolimus levels → toxicity/nephrotoxicity); azole antifungals fluconazole, itraconazole, voriconazole, posaconazole (similarly potent CYP3A4 inhibitors); diltiazem and verapamil (moderate CYP3A4 inhibitors); HIV protease inhibitors; grapefruit (CYP3A4 inhibition). Rifampicin is a potent CYP3A4 inducer — causes precipitous drop in tacrolimus levels → rejection risk. St John's wort: inducer — can cause rejection; many patients don't mention it. Probenecid and ACE inhibitors/ARBs can affect tacrolimus levels or renal function in the transplant. NSAIDs: avoid — reduce GFR, risk of acute kidney injury in transplant. Always check AMH or contact the transplant pharmacist before adding any new medication.
What vaccinations does a kidney transplant patient need?

All vaccinations must be inactivated — live vaccines are permanently contraindicated post-transplant. The ATAGI immunocompromised schedule applies: annual inactivated influenza (essential — infections trigger rejection); COVID-19 booster doses (higher doses and more frequent recommended for solid organ transplant patients per TGA/ATAGI guidance); Prevenar 20 (or Prevenar 13 → PPSV23 at 8 weeks, repeat at 5 years); MenACWY + MenB; Hib; hepatitis A + B complete series; dTpa. Shingrix (recombinant, non-live zoster vaccine) is NIP-funded for severely immunocompromised adults since 2023. Catch-up live vaccines (MMR, varicella) must occur before transplant, not after.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.